UA105496C2 - Доставка октреотиду сухими фармакологічними формами - Google Patents

Доставка октреотиду сухими фармакологічними формами

Info

Publication number
UA105496C2
UA105496C2 UAA201101452A UAA201101452A UA105496C2 UA 105496 C2 UA105496 C2 UA 105496C2 UA A201101452 A UAA201101452 A UA A201101452A UA A201101452 A UAA201101452 A UA A201101452A UA 105496 C2 UA105496 C2 UA 105496C2
Authority
UA
Ukraine
Prior art keywords
octreotide
delivery
dry formulations
composition
delivering
Prior art date
Application number
UAA201101452A
Other languages
English (en)
Russian (ru)
Inventor
Петр Кузма
Стефані Декер
Original Assignee
Ендо Фармас'Ютікалз Солюшнз Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ендо Фармас'Ютікалз Солюшнз Інк. filed Critical Ендо Фармас'Ютікалз Солюшнз Інк.
Publication of UA105496C2 publication Critical patent/UA105496C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Винахід стосується способів і пристроїв для доставки октреотиду пацієнтам, які передбачають імплантацію пристрою у сухому стані, що включає композицію, яка містить 84 мг октреотиду ацетату, 9,5 мг гідроксипропілцелюлози та 2 мг стеарату магнію. Композиція розміщена в гідрофільному полімері.
UAA201101452A 2008-07-11 2009-07-10 Доставка октреотиду сухими фармакологічними формами UA105496C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/171,999 US7759312B2 (en) 2005-03-11 2008-07-11 Delivery of dry formulations of octreotide
PCT/US2009/050215 WO2010006236A1 (en) 2008-07-11 2009-07-10 Delivery of dry formulations of octreotide

Publications (1)

Publication Number Publication Date
UA105496C2 true UA105496C2 (uk) 2014-05-26

Family

ID=41268227

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201101452A UA105496C2 (uk) 2008-07-11 2009-07-10 Доставка октреотиду сухими фармакологічними формами

Country Status (14)

Country Link
US (4) US7759312B2 (uk)
EP (1) EP2309979A1 (uk)
JP (2) JP2011527705A (uk)
KR (1) KR20110038056A (uk)
CN (1) CN102231977A (uk)
AU (1) AU2009268480C1 (uk)
BR (1) BRPI0915523A2 (uk)
CA (1) CA2730391C (uk)
IL (1) IL210545A (uk)
MX (1) MX336209B (uk)
RU (1) RU2518745C2 (uk)
UA (1) UA105496C2 (uk)
WO (1) WO2010006236A1 (uk)
ZA (1) ZA201100800B (uk)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
EP2457564A1 (en) * 2005-03-11 2012-05-30 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
RU2463079C2 (ru) * 2007-04-27 2012-10-10 Эндо Фармасьютикалз Солюшнз Инк. Разделительные агенты для имплантируемого устройства и способы их применения
KR20110025974A (ko) * 2008-06-25 2011-03-14 엔도 파마슈티컬즈, 솔루션스 아이엔씨. 이형제를 함유하는 옥트레오티드 이식물
WO2009158412A2 (en) * 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
CA2963659C (en) 2008-09-17 2020-06-23 Chiasma Inc. Use of oral octreotride compositions
CN103039688B (zh) 2012-01-20 2016-01-06 奥驰亚客户服务公司 口腔用产品
CN102754907B (zh) 2012-01-20 2015-06-24 奥驰亚客户服务公司 口腔用产品
CN102754908B (zh) * 2012-01-20 2015-06-10 奥驰亚客户服务公司 口腔用烟草产品
CN103040090B (zh) 2012-01-20 2016-03-30 奥驰亚客户服务公司 脱除烟草的口腔用产品
US9854831B2 (en) 2012-01-20 2018-01-02 Altria Client Services Llc Oral product
CA2918787A1 (en) * 2013-06-13 2014-12-18 George Tachas Combination therapy
EP3253401A4 (en) 2015-02-03 2018-11-21 Chiasma Inc. Method of treating diseases
CN110732037B (zh) 2018-07-20 2023-05-26 广州倍绣生物技术有限公司 止血糊剂及其制备方法
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
TW202339747A (zh) * 2022-01-11 2023-10-16 美商克林提克斯醫藥股份有限公司 生長抑制素調節劑用於治療類癌症候群(carcinoid syndrome)之用途

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2265226A (en) * 1936-10-17 1941-12-09 Du Pont Cast resins having integral sheen
US2513014A (en) * 1946-11-18 1950-06-27 Abbott Lab Apparatus for implanting medicinal pellets subcutaneously
US3975350A (en) * 1972-08-02 1976-08-17 Princeton Polymer Laboratories, Incorporated Hydrophilic or hydrogel carrier systems such as coatings, body implants and other articles
US3921632A (en) * 1974-08-16 1975-11-25 Frank M Bardani Implant device
US4131604A (en) * 1977-11-23 1978-12-26 Thermo Electron Corporation Polyurethane elastomer for heart assist devices
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4298002A (en) * 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
US4386039A (en) * 1980-02-11 1983-05-31 Thermo Electron Corporation Process for forming an optically clear polyurethane lens or cornea
US4523005A (en) * 1981-10-30 1985-06-11 Thermedics, Inc. Extrudable polyurethane for prosthetic devices prepared from a diisocyanate, a polytetramethylene ether polyol, and 1,4-butane diol
US4751133A (en) * 1984-11-13 1988-06-14 Thermedics, Inc. Medical patches and processes for producing same
US5342622A (en) * 1986-05-16 1994-08-30 The State Of Victoria Subdermal biocompatible implants
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4743673A (en) * 1986-12-19 1988-05-10 Tyndale Plains-Hunter, Ltd. Hydrophilic carboxy polyurethanes
US4871094A (en) * 1986-12-31 1989-10-03 Alcon Laboratories, Inc. Means and method for dispensing substances
US4994028A (en) * 1987-03-18 1991-02-19 Endocon, Inc. Injector for inplanting multiple pellet medicaments
AU608891B2 (en) 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
US5035891A (en) * 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US4954587A (en) * 1988-07-05 1990-09-04 Ciba-Geigy Corporation Dimethylacrylamide-copolymer hydrogels with high oxygen permeability
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5468811A (en) * 1989-11-02 1995-11-21 National Patent Development Corporation Hydrophilic composite polymer articles formed from a settable paste comprising a mixture of hydrophilic polymer and unsaturated monomer
US5254662A (en) * 1990-09-12 1993-10-19 Polymedia Industries, Inc. Biostable polyurethane products
US5266325A (en) * 1990-09-28 1993-11-30 Hydro Med Science Division Of National Patent Development Corp. Preparation of homogeneous hydrogel copolymers
ATE106015T1 (de) * 1990-09-28 1994-06-15 Pfizer Wirkstoffabgabevorrichtung die ein hydrophobisches mittel enthält.
AU651654B2 (en) * 1992-01-14 1994-07-28 Endo Pharmaceuticals Solutions Inc. Manufacture of water-swellable hydrophilic articles and drug delivery devices
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
AU652984B2 (en) 1992-01-14 1994-09-15 Endo Pharmaceuticals Solutions Inc. Preparation of homogeneous hydrogel copolymers
JP2530079B2 (ja) 1992-02-05 1996-09-04 ナショナル・パテント・ディベロプメント・コーポレーション 水分膨潤性親水性製品及び薬物放出装置の製造
US5428123A (en) * 1992-04-24 1995-06-27 The Polymer Technology Group Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range
US5614223A (en) * 1992-05-04 1997-03-25 Digestive Care Inc. Intraoral medicament-releasing device
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
DE69425781T2 (de) * 1993-06-11 2001-01-04 Nippon Chemicon Understützungs- und Verbindungsgerät für einen Magnetfeldmodulationskopf, der in einer photomagnetischen Aufzeichnung benutzt wird
US5354835A (en) * 1993-07-23 1994-10-11 Saudi Basic Industries Corporation Desalination process
KR950007873A (ko) 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
JPH07252166A (ja) 1993-09-20 1995-10-03 Shiseido Co Ltd 徐放性製剤
JPH0797338A (ja) 1993-09-20 1995-04-11 Shiseido Co Ltd 徐放性製剤
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US6956026B2 (en) * 1997-01-07 2005-10-18 Amylin Pharmaceuticals, Inc. Use of exendins for the reduction of food intake
CN1216636C (zh) * 1996-08-30 2005-08-31 派普泰克有限公司 肽缓释组合物
US5945128A (en) * 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
AUPO251096A0 (en) * 1996-09-23 1996-10-17 Cardiac Crc Nominees Pty Limited Polysiloxane-containing polyurethane elastomeric compositions
US5756127A (en) * 1996-10-29 1998-05-26 Wright Medical Technology, Inc. Implantable bioresorbable string of calcium sulfate beads
US5854127A (en) * 1997-03-13 1998-12-29 Micron Technology, Inc. Method of forming a contact landing pad
FI971385A0 (fi) 1997-04-04 1997-04-04 Bioxid Oy Biokompatibel komposition, metoder foer dess framstaellning samt anvaendning daerav
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7157555B1 (en) * 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7220721B1 (en) * 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US6822016B2 (en) * 2001-09-10 2004-11-23 Johnson & Johnson Vision Care, Inc. Biomedical devices containing internal wetting agents
WO2000004037A1 (en) * 1998-07-14 2000-01-27 Amylin Pharmaceuticals, Inc. Uncoupling protein 4 (ucp-4) and methods of use
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
US20040071736A1 (en) * 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
US7259136B2 (en) * 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
PT1143989E (pt) * 1999-01-14 2007-03-30 Amylin Pharmaceuticals Inc Exendinas para supressão de glucagon
AU757605B2 (en) 1999-01-28 2003-02-27 Indevus Pharmaceuticals, Inc. Hydrogel compositions useful for the sustained release of macromolecules and methods of making same
US6454933B2 (en) * 1999-08-26 2002-09-24 Exxonmobil Research And Engineering Company Fluid atomization process
US20030036504A1 (en) * 2000-01-10 2003-02-20 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
MXPA02009031A (es) * 2000-03-14 2004-08-19 Amylin Pharmaceuticals Inc Efectos del peptido-1(7-36) tipo glucagon en la motilidad antro-piloro.duodenal.
US6969480B2 (en) * 2000-05-12 2005-11-29 Matregen Corp. Method of producing structures using centrifugal forces
AU6323001A (en) * 2000-05-19 2001-12-03 Bionebraska Inc Treatment of acute coronary syndrome with glp-1
JP3498041B2 (ja) * 2000-05-29 2004-02-16 科研製薬株式会社 プラルモレリン含有点鼻用製剤
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
BR0116206A (pt) * 2000-12-14 2003-12-23 Amylin Pharmaceuticals Inc Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos
US20050004000A1 (en) 2001-04-01 2005-01-06 Yoram Shechter Oral absorbed drugs
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
ATE494002T1 (de) * 2002-06-14 2011-01-15 Amylin Pharmaceuticals Inc Prävention und/oder behandlung von colitis ulcerosa mit pyy oder pyyä3-36ü
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
US6942264B1 (en) * 2003-02-10 2005-09-13 Richard Mendez Disposable pet waste receptacle
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
WO2005021023A1 (en) * 2003-09-02 2005-03-10 Pharmacia & Upjohn Company Therapeutical conversion
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
FR2870398B1 (fr) * 2004-05-12 2006-07-07 Canon Europa Nv Naamlooze Venn Dispositif de connexion securisee et fiche de connexion correspondante
EP1773293B1 (en) * 2004-06-17 2015-04-15 Endo Pharmaceuticals Solutions Inc. Compositions and methods for treating central precocious puberty
SE0402345L (sv) * 2004-09-24 2006-03-25 Mederio Ag Uppmätt läkemedelsdos
EP2457564A1 (en) * 2005-03-11 2012-05-30 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
US20070037897A1 (en) * 2005-08-12 2007-02-15 Guigui Wang Method for making contact lenses
US20090181887A1 (en) 2005-09-08 2009-07-16 Gastrotech Pharma A/S Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
RU2463079C2 (ru) * 2007-04-27 2012-10-10 Эндо Фармасьютикалз Солюшнз Инк. Разделительные агенты для имплантируемого устройства и способы их применения
KR20110025974A (ko) * 2008-06-25 2011-03-14 엔도 파마슈티컬즈, 솔루션스 아이엔씨. 이형제를 함유하는 옥트레오티드 이식물
WO2009158412A2 (en) * 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides

Also Published As

Publication number Publication date
EP2309979A1 (en) 2011-04-20
US20100247594A1 (en) 2010-09-30
RU2518745C2 (ru) 2014-06-10
US20090035343A1 (en) 2009-02-05
MX2011000354A (es) 2011-04-05
US7759312B2 (en) 2010-07-20
MX336209B (es) 2016-01-11
CN102231977A (zh) 2011-11-02
WO2010006236A1 (en) 2010-01-14
CA2730391C (en) 2016-12-06
JP2011527705A (ja) 2011-11-04
JP5840758B2 (ja) 2016-01-06
AU2009268480A1 (en) 2010-01-14
JP2015071632A (ja) 2015-04-16
US20190388500A1 (en) 2019-12-26
US20170049850A1 (en) 2017-02-23
ZA201100800B (en) 2011-10-26
BRPI0915523A2 (pt) 2016-01-26
IL210545A (en) 2015-06-30
KR20110038056A (ko) 2011-04-13
RU2011105029A (ru) 2012-08-20
CA2730391A1 (en) 2010-01-14
AU2009268480C1 (en) 2015-04-09
IL210545A0 (en) 2011-03-31
AU2009268480B2 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
MX336209B (es) Suministro de formulaciones secas de octreótido.
MY156383A (en) Pharmaceutical compositions
HK1145803A1 (en) Devices, formulations, and methods for delivery of multiple beneficial agents
HRP20171223T1 (hr) Poboljšane formulacije i postupci liofiliziranja i tako dobiveni liofilizati
WO2009009688A9 (en) Delivery system
MY171625A (en) Injectable flowable composition comprising buprenorphine
MX2009012690A (es) Composiciones, metodos, dispositivos y sistemas para el cuidado bucal.
HK1141441A1 (en) Sustained release pellets comprising wax-like material
MX358435B (es) Capsula de estradiol soluble para insercion por via vaginal.
MY161593A (en) Oral formulations of cytidine analogs and methods of use thereof
UA104866C2 (uk) Імплантат октреотиду, який містить вивільняючу речовину
MY150626A (en) Fast dissolving solid dosage form
MY161595A (en) Oral care compositions
EP2240165A4 (en) CARRIER COMPOSITIONS WITH SOLUBLE HYDROPHOBIC CORE FOR THE RELEASE OF THERAPEUTICS, MANUFACTURING METHOD AND USER METHOD THEREFOR
MX2012007365A (es) Composiciones farmaceuticas de liberacion lenta de iloperidona.
MY191875A (en) Solid dosage form
WO2012048170A3 (en) Humanized animals via tissue engineering and uses therefor
MX2007013327A (es) Formulaciones de liberacion prolongada.
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
MX2013012259A (es) Analogos del factor de liberacion de la hormona de crecimiento (grf) y usos de estos.
MX2012015102A (es) Agentes terapeuticos 976.
MX336065B (es) Composiciones con liberacion rapida de farmaco.
MX2008002272A (es) Compuestos de ciclopropilo y composiciones para suministrar agentes activos.
IL221333B (en) Antibiotic topical formulations
ZA200904563B (en) Transdermal Therapeutic system for administering water-soluble active ingredients